Quercetin for Diabetes and Insulin Resistance: Could Nature's SGLT-2 Inhibitor Support Better Metabolic Health?
- David Stephen Klein, MD FACA FACPM
- 2 days ago
- 13 min read
Quick Look
Quercetin is a naturally occurring plant compound found in onions, apples, berries, capers, and many other colorful foods. It is best known for its antioxidant and anti-inflammatory properties, but research suggests that certain forms of quercetin may also influence how the intestine and kidneys handle glucose.
This has led some researchers to ask whether quercetin might produce a mild version of certain effects associated with prescription sodium-glucose cotransporter-2, or SGLT-2, inhibitors. These medications lower blood sugar, promote modest weight loss, and protect the heart and kidneys. Emerging observational research also raises the possibility that they could reduce the occurrence of certain cancers, although this has not been proved.
Quercetin is not equivalent to an SGLT-2 medication and should not be used as a substitute for prescribed diabetes treatment. Nevertheless, its effects on glucose regulation, inflammation, blood vessels, and insulin sensitivity make it an intriguing component of a broader metabolic-health strategy.
A Plant Compound With Broad Biological Activity
Quercetin belongs to a large family of plant nutrients known as flavonoids. Plants produce flavonoids partly to protect themselves from ultraviolet radiation, infection, oxidation, and environmental stress. When consumed by humans, some of these compounds appear to influence protective cellular pathways.
Quercetin has been studied for possible effects on:
insulin sensitivity
inflammation
oxidative stress
blood pressure
blood-vessel function
mitochondrial health
immune regulation
Human trials suggest that quercetin supplementation may modestly reduce insulin levels and systolic blood pressure in some populations, although effects on fasting glucose, hemoglobin A1c, cholesterol, and body weight have been inconsistent.¹⁻³ This is an important distinction. Quercetin has promising biological activity, but many of its proposed benefits remain more convincing in laboratory and animal studies than in large human clinical trials.
Understanding the SGLT System
The kidneys continuously filter the blood. Glucose passes into this filtered fluid, but under normal circumstances, nearly all of it is returned to the bloodstream rather than lost in the urine.
This glucose recovery is accomplished primarily by proteins called sodium-glucose cotransporters. SGLT-2 is located mainly in the first portion of the kidney tubule and is responsible for reclaiming most of the glucose filtered by the kidneys. SGLT-1 completes much of the remaining glucose reabsorption and also helps absorb glucose from the intestine.
When SGLT-2 is inhibited:
less glucose returns to the bloodstream
more glucose leaves the body in the urine
blood glucose decreases
some calories are lost
insulin requirements may decline
blood pressure may fall slightly
pressure within the kidney’s filtering system improves
This mechanism led to the development of prescription medications including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.
SGLT-2 inhibitors were originally developed to lower blood glucose in people with type 2 diabetes. Their mechanism seemed straightforward: allow some of the filtered glucose to leave through the urine rather than returning it to the bloodstream.
What followed was unexpected.
Large clinical trials demonstrated that the benefits of these medications extend well beyond hemoglobin A1c. SGLT-2 inhibitors consistently reduce hospitalization for heart failure and slow the progression of chronic kidney disease. These benefits can occur even when their effect on blood glucose is relatively modest.⁴⁻⁶
The medications are now used not only in diabetes but also in many patients with heart failure or chronic kidney disease who do not have diabetes. Their evolution illustrates an important principle: improving metabolic health involves much more than lowering a laboratory glucose value.
SGLT-2 Inhibitors and Weight Loss
Each gram of glucose lost through the urine carries calories with it. Over time, this produces a modest caloric deficit.
Most patients lose a relatively small amount of weight rather than experiencing the dramatic weight reduction sometimes seen with GLP-1 medications. Across clinical trials, the average reduction is commonly in the range of several pounds. The response varies according to the medication, dose, kidney function, diet, baseline weight, and duration of treatment.⁷⁻⁹
The weight loss appears to come primarily from fat mass, although some studies have also raised concern about small reductions in lean tissue, particularly in older adults. For that reason, adequate dietary protein and resistance exercise remain important when these medications are used in aging patients.
SGLT-2 inhibitors should therefore not be considered primary weight-loss medications. Their value lies in the combination of modest weight reduction with improved glucose regulation, lower blood pressure, and meaningful heart and kidney protection.
Persistently elevated glucose can impair the function of insulin-producing pancreatic beta cells and worsen insulin resistance. This process is sometimes called glucotoxicity.
By removing glucose through the urine, SGLT-2 inhibitors reduce the amount of glucose that must be handled by insulin. This does not directly reverse every cause of insulin resistance, but it can reduce the metabolic burden created by chronic hyperglycemia.
In practical terms, the body does not have to produce as much insulin to manage the same glucose load. This may be particularly helpful when diabetes is accompanied by obesity, fatty liver disease, hypertension, or chronic kidney disease.
SGLT-2 inhibitors reduce pressure inside the kidney’s filtering units and can slow the decline of kidney function. They also promote mild sodium and fluid loss, improve cardiac energy use, and reduce the likelihood of fluid overload.
Across major clinical trials and meta-analyses, the most consistent benefits have been:
fewer hospitalizations for heart failure
slower progression of chronic kidney disease
fewer serious kidney outcomes
reduced cardiovascular risk in selected high-risk patients
These protective effects are now considered central features of the drug class rather than secondary benefits.⁴⁻⁶
Could SGLT-2 Inhibitors Reduce Cancer Prevalence?
Diabetes, obesity, hyperinsulinemia, and chronic inflammation are associated with increased risk for several forms of cancer. It is therefore reasonable to ask whether improving these metabolic disturbances might also affect cancer risk.
Recent observational studies and meta-analyses have reported lower overall cancer rates among some patients using SGLT-2 inhibitors compared with patients using certain other diabetes medications. Possible reductions have been reported for liver, lung, prostate, gastrointestinal, and other cancers.¹⁰⁻¹²
These findings are intriguing, but they must be interpreted cautiously. The available evidence is not fully consistent. Some analyses show a lower incidence of selected cancers, others find an overall neutral effect, and a few have raised questions about individual cancer categories. Much of the apparent benefit comes from observational data rather than randomized trials designed specifically to study cancer prevention.¹⁰⁻¹³
Patients prescribed SGLT-2 inhibitors may also differ from comparison groups in weight, kidney function, smoking history, medication use, access to health care, and other factors that influence cancer risk.
At present, SGLT-2 inhibitors should not be prescribed as cancer-prevention drugs. The most accurate conclusion is that they do not appear to increase overall cancer risk, and emerging evidence suggests they might reduce the occurrence of some cancers. Whether this represents a direct anticancer effect or an indirect benefit of improved metabolic health remains unsettled.
Can Quercetin Do Something Similar?
This is where the discussion becomes both interesting and easily overstated. Certain quercetin compounds—particularly quercetin glucosides—interact with sodium-glucose transporters in laboratory studies. The strongest direct evidence involves intestinal SGLT-1, where quercetin glucosides can compete with glucose transport and reduce glucose uptake.¹⁴⁻¹⁶
The evidence that ordinary supplemental quercetin meaningfully inhibits kidney SGLT-2 in humans is much less developed. Some laboratory and computer-modeling studies suggest possible interaction with glucose transport pathways, but this has not been established as a clinically important renal effect. Quercetin should therefore not be described simply as a natural equivalent of empagliflozin or dapagliflozin.
A more accurate interpretation is that quercetin may influence glucose handling through several pathways, potentially including intestinal glucose absorption, insulin signaling, inflammation, oxidative stress, and cellular glucose transport. Any direct SGLT-2 effect in humans remains investigational.
Clinical Pearl
One of the advantages of many nutritional compounds is also one of the reasons they are difficult to study: they may influence several pathways at once. Quercetin does not appear to act as a powerful, single-target medication. Instead, it may modestly affect glucose absorption while also influencing inflammation, oxidative stress, vascular function, mitochondrial activity, and insulin signaling.
This broader activity may complement a comprehensive metabolic program, but it also means that quercetin’s effects cannot be assumed to match those of a prescription SGLT-2 inhibitor.
Quercetin and Insulin Resistance
Insulin resistance develops when muscle, liver, fat, and other tissues become less responsive to insulin. The pancreas compensates by producing more insulin. Blood sugar may remain within the conventional laboratory range for years while insulin levels steadily rise. Eventually, the pancreas may no longer produce enough insulin to overcome the resistance. Glucose then rises into the ranges labeled prediabetes and type 2 diabetes.
Quercetin may support insulin sensitivity by:
reducing oxidative stress that interferes with insulin signaling
decreasing inflammatory signaling
influencing enzymes involved in glucose metabolism
supporting endothelial and mitochondrial function
possibly reducing intestinal glucose absorption in certain forms
Clinical evidence remains mixed. A meta-analysis of randomized trials found that quercetin may reduce fasting glucose under certain conditions, particularly with doses of at least 500 milligrams daily and treatment lasting eight weeks or longer. A later analysis found a reduction in insulin but not consistent improvements across all cardiometabolic measures.¹,²
The most defensible conclusion is that quercetin may provide modest metabolic support, but it is not a reliably proven treatment for diabetes or insulin resistance by itself.
Could Quercetin Assist With Weight Management?
Quercetin has been associated with changes in fat metabolism, inflammation, and mitochondrial function in laboratory research. Animal studies have also suggested possible effects on fat accumulation and energy regulation. Human evidence for meaningful weight loss, however, is limited and inconsistent.
Quercetin does not cause urinary calorie loss comparable to prescription SGLT-2 inhibitors, and it should not be presented as a stand-alone weight-loss supplement. Any benefit is more likely to be indirect—for example, through improved metabolic flexibility, reduced inflammation, or better support of insulin signaling. Weight reduction still depends primarily on nutrition, physical activity, muscle preservation, sleep, hormonal health, and correction of the underlying factors driving insulin resistance.
Quercetin, Inflammation, and Cancer Biology
Quercetin has demonstrated anticancer activity in cell and animal models. It has been studied for its effects on oxidative stress, inflammatory signaling, cell-cycle regulation, apoptosis, and pathways involved in tumor growth.³
However, laboratory anticancer activity does not prove that taking quercetin supplements reduces cancer prevalence in humans. There is currently insufficient clinical evidence to recommend quercetin as a cancer-prevention or cancer-treatment agent. Patients undergoing cancer treatment should also discuss supplementation with their oncology team because antioxidants and plant compounds may interact with chemotherapy, radiation, anticoagulants, or other medications.
Its most reasonable role is as one component of a plant-rich dietary pattern that supports overall metabolic health—not as a replacement for cancer screening, medical evaluation, or established treatment.
Beyond Blood Sugar
Quercetin’s potential value may extend beyond its effect on glucose.
Inflammation
Quercetin can influence inflammatory signaling pathways, including NF-κB and several inflammatory cytokines. Most dramatic findings come from preclinical research, while human responses tend to be smaller and more variable.³
Blood-Vessel Function
Oxidative stress can reduce nitric oxide availability and impair normal blood-vessel relaxation. Quercetin may support endothelial function and has produced modest reductions in blood pressure in some clinical studies.²,³
Oxidative Stress
Quercetin can interact directly with reactive oxygen species and may also influence the body’s own antioxidant-defense systems.
Mitochondrial Health
Preclinical evidence suggests that quercetin may support mitochondrial signaling and energy metabolism. Whether this produces clinically meaningful improvements in longevity remains unknown.
These diverse actions are biologically interesting, but they should be viewed as supportive mechanisms rather than proof that quercetin prevents specific diseases.
Food Sources of Quercetin
Quercetin is naturally present in:
capers
red and yellow onions
apples, especially the peel
berries
cherries
kale
broccoli
asparagus
tea
grapes
Capers and onions are among the richest commonly consumed sources. The amount absorbed varies according to the food, its preparation, the form of quercetin present, intestinal function, and the gut microbiome.
A colorful, plant-rich diet provides quercetin together with fiber, minerals, vitamins, and many other phytonutrients that may work collectively.
Should You Take a Quercetin Supplement?
Supplemental doses used in human studies commonly range from approximately 500 to 1,000 milligrams daily, although there is no universally accepted dose for treating insulin resistance or diabetes.
Quercetin is absorbed imperfectly, and formulations vary substantially. Some products combine it with vitamin C, bromelain, phospholipids, or specialized delivery systems intended to improve absorption.
More absorption is not automatically better. A highly bioavailable formulation may produce different effects and interactions than traditional quercetin preparations.
Patients should discuss supplementation with a knowledgeable clinician, especially when taking:
anticoagulants or antiplatelet medications
diabetes medications
blood-pressure medications
immunosuppressive drugs
chemotherapy
multiple prescription medications
Quercetin should not be used to replace metformin, an SGLT-2 inhibitor, a GLP-1 medication, insulin, or another prescribed therapy.
Safety
Quercetin is generally well tolerated in short-term human studies. Reported adverse effects may include:
stomach discomfort
nausea
headache
tingling sensations
Long-term safety data at high supplemental doses remain less complete. Caution is appropriate in patients with significant kidney disease, during pregnancy, and when quercetin is combined with medications that have narrow therapeutic ranges.
Patients taking both quercetin and prescription glucose-lowering therapy should monitor glucose appropriately. Although quercetin alone is unlikely to produce the glucose-lowering potency of an SGLT-2 medication, combinations can sometimes behave differently than expected.
What We Still Do Not Know
Important unanswered questions include:
whether supplemental quercetin meaningfully inhibits renal SGLT-2 in humans
which quercetin forms best influence intestinal glucose absorption
whether it produces durable improvements in hemoglobin A1c
whether it meaningfully assists with weight loss
whether it reduces diabetes complications
whether it adds benefit to prescription SGLT-2 therapy
which formulations and doses provide the best balance of absorption and safety
whether its preclinical anticancer effects translate into reduced cancer incidence in humans
These questions require larger, longer, well-controlled clinical trials.
Bottom Line
Quercetin is a biologically active plant compound with potentially useful effects on inflammation, oxidative stress, vascular function, insulin signaling, and glucose handling.
Certain quercetin glucosides can interact with intestinal SGLT-1, and emerging laboratory research has raised interest in other glucose-transport pathways. However, quercetin has not been shown to reproduce the renal SGLT-2 inhibition or the proven heart and kidney outcomes associated with prescription SGLT-2 medications.
Prescription SGLT-2 inhibitors can lower blood glucose, promote modest weight loss, reduce heart-failure hospitalization, and slow kidney disease. Emerging research also suggests a possible reduction in certain cancers, but this remains unproven and should not yet be considered an established benefit.
Quercetin may serve as a useful nutritional adjunct within a comprehensive plan for insulin resistance and metabolic health. It should not be regarded as a natural replacement for diabetes medication, medical weight-loss treatment, cancer screening, or individualized medical care.
Continue Your Journey to Better Health
Metabolic dysfunction rarely involves blood sugar alone. Insulin resistance interacts with inflammation, mitochondrial function, liver health, vascular health, body composition, sleep, nutrition, and hormonal regulation. Exploring these interconnected systems can help identify metabolic changes long before diabetes and its complications become firmly established.
Continue your journey with these related articles from Stages of Life Medical Institute:
Become a Patient
At Stages of Life Medical Institute, we evaluate metabolic health using more than fasting glucose alone. Depending on the individual, assessment may include hemoglobin A1c, fasting insulin, lipid patterns, liver markers, kidney function, inflammation, hormone balance, body composition, and other indicators of metabolic stress.
Our goal is to identify insulin resistance early and create an individualized plan incorporating nutrition, movement, sleep, appropriate supplementation, and prescription treatment when medically indicated.
At Stages of Life Medical Institute, we believe symptoms rarely occur in isolation. Instead, they reflect complex interactions among genetics, nutrition, hormones, metabolism, inflammation, environmental exposures, and lifestyle. Our systems-based approach seeks to identify and address these root causes, helping patients achieve lasting health rather than simply treating individual symptoms.
References
Ostadmohammadi V, Milajerdi A, Ayati E, et al. Effects of quercetin supplementation on glycemic control among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019;33(5):1330–1340. PubMed
Arabi SM, Bahrami LS, Rahnama I, Sahebkar A. The effects of quercetin supplementation on cardiometabolic parameters: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2023. PubMed
Aghababaei F, Hadidi M. Recent advances in potential health benefits of quercetin. Pharmaceuticals. 2023;16(7):1020. PubMed Central
McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–158. PubMed
Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–1250. PubMed
Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10(1):1–10. PubMed
Cai X, Yang W, Gao X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity. 2018;26(1):70–80. PubMed
Wang H, Yang J, Chen X, Qiu F. Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Clin Ther. 2019;41(2):322–334.e11. PubMed
Cho YK, Kim YJ, Jung CH. Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and meta-analysis. J Obes Metab Syndr. 2021;30(4):336–344. PubMed
Hajishah H, et al. Comparative risk of cancer associated with SGLT inhibitors versus DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis. 2025. PubMed
Xu B, et al. Association between sodium-glucose cotransporter-2 inhibitors and cancer risk in patients with type 2 diabetes mellitus. 2025. PubMed
Wang Y, et al. Impact of SGLT2 inhibitors on tumor development risk in patients with type 2 diabetes mellitus. 2025. PubMed Central
Spiazzi BF, et al. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023. PubMed
Ader P, Blöck M, Pietzsch S, Wolffram S. Interaction of quercetin glucosides with the intestinal sodium/glucose cotransporter. Cancer Lett. 2001;162(2):175–180. PubMed
Wolffram S, Blöck M, Ader P. Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush-border membrane of rat small intestine. J Nutr. 2002;132(4):630–635. PubMed
Cermak R, Landgraf S, Wolffram S. Quercetin glucosides inhibit glucose uptake into brush-border-membrane vesicles of porcine jejunum. Br J Nutr. 2004;91(6):849–855. PubMed
The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances.
1917 Boothe Circle, Suite 171
Longwood, Florida 32750
Tel: 407-679-3337
Fax: 407-678-7246
.webp)